4/7
07:45 am
hura
TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations
Medium
Report
TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations
4/7
01:05 am
hura
Low
Report
4/2
06:37 am
hura
TuHURA Biosciences, Inc.'s (NASDAQ:HURA) Shift From Loss To Profit [Yahoo! Finance]
High
Report
TuHURA Biosciences, Inc.'s (NASDAQ:HURA) Shift From Loss To Profit [Yahoo! Finance]
4/1
07:57 am
hura
TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update [TheStreet.com]
High
Report
TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update [TheStreet.com]
4/1
07:45 am
hura
TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
High
Report
TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
3/30
01:04 am
hura
Medium
Report
3/23
08:00 am
hura
Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers [Yahoo! Finance]
Medium
Report
Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers [Yahoo! Finance]
3/23
07:45 am
hura
Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers
High
Report
Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers
3/22
01:04 am
hura
Low
Report
2/27
08:00 am
hura
TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement [Yahoo! Finance]
Medium
Report
TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement [Yahoo! Finance]
2/27
07:30 am
hura
TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement
Medium
Report
TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement
2/24
05:20 pm
hura
TuHURA Biosciences Announces Participation in Upcoming Investor Conferences
High
Report
TuHURA Biosciences Announces Participation in Upcoming Investor Conferences
2/17
07:45 am
hura
TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers
High
Report
TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers
2/12
07:58 am
hura
TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
Medium
Report
TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
2/12
07:45 am
hura
TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Medium
Report
TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
2/3
08:03 am
hura
TuHURA Biosciences (NASDAQ:HURA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
TuHURA Biosciences (NASDAQ:HURA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
2/2
08:11 am
hura
TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma [Yahoo! Finance]
Medium
Report
TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma [Yahoo! Finance]
2/2
07:45 am
hura
TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma
High
Report
TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma
1/24
05:10 am
hura
TuHURA Biosciences (NASDAQ:HURA) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
TuHURA Biosciences (NASDAQ:HURA) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.